Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center open-label parallel group randomized controlled trial to compare iGlarLixi versus premixed insulin in patients with type 2 diabetes who have failed to achieve glycemic control with basal insulin and oral antidiabetic agents

Next Previous
Search
Trial Profile

A multi-center open-label parallel group randomized controlled trial to compare iGlarLixi versus premixed insulin in patients with type 2 diabetes who have failed to achieve glycemic control with basal insulin and oral antidiabetic agents

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin aspart/insulin protamine aspart
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms Global Premix; Solimix
  • Sponsors Sanofi

    • Most Recent Events

    • 22 Feb 2024 Results of pooled analysis of four studies (LixiLan-O, LixiLan-G, LixiLan-L, SoliMix) assessing efficacy and safety of iGlarLixi in older people (≥65 years) with type 2 diabetes (T2D) advancing or switching from oral agents, published in the Diabetes, Obesity and Metabolism.
    • 03 Aug 2023 Results of sub analysis of the SoliMix trial in participants in Latin American countries published in the Diabetes, Obesity and Metabolism
    • 26 Jun 2023 Results of a post-hoc pooled analysis assessing factors associated with achieving target HbA1c <7.0% in people with type 2 diabetes treated with iGlarLixi from four clinical trials: NCT02058147, NCT02058160, NCT02787551 and EudraCT2017-003370-13 presented at the 83rd Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top